IL311229A - Triple-agent therapy for cancer treatment - Google Patents

Triple-agent therapy for cancer treatment

Info

Publication number
IL311229A
IL311229A IL311229A IL31122924A IL311229A IL 311229 A IL311229 A IL 311229A IL 311229 A IL311229 A IL 311229A IL 31122924 A IL31122924 A IL 31122924A IL 311229 A IL311229 A IL 311229A
Authority
IL
Israel
Prior art keywords
cancer treatment
factor therapy
therapy
factor
cancer
Prior art date
Application number
IL311229A
Other languages
English (en)
Hebrew (he)
Inventor
Larry Weisenthal
William Grace
Original Assignee
Cytometric Therapeutics Inc
Larry Weisenthal
William Grace
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytometric Therapeutics Inc, Larry Weisenthal, William Grace filed Critical Cytometric Therapeutics Inc
Publication of IL311229A publication Critical patent/IL311229A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL311229A 2021-09-15 2022-09-15 Triple-agent therapy for cancer treatment IL311229A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163244412P 2021-09-15 2021-09-15
PCT/US2022/043601 WO2023043883A1 (en) 2021-09-15 2022-09-15 Triple-agent therapy for cancer treatment

Publications (1)

Publication Number Publication Date
IL311229A true IL311229A (en) 2024-05-01

Family

ID=85603487

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311229A IL311229A (en) 2021-09-15 2022-09-15 Triple-agent therapy for cancer treatment

Country Status (10)

Country Link
US (1) US12611411B2 (https=)
EP (1) EP4401720A4 (https=)
JP (1) JP2024531765A (https=)
KR (1) KR20240060625A (https=)
CN (1) CN118159262A (https=)
AU (1) AU2022345084A1 (https=)
CA (1) CA3231639A1 (https=)
IL (1) IL311229A (https=)
MX (1) MX2024003333A (https=)
WO (1) WO2023043883A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2644194T3 (en) * 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
US20100189683A1 (en) 2008-11-14 2010-07-29 Ascenta Therapeutics, Inc. Pulsatile Dosing of Gossypol for Treatment of Disease
KR101874390B1 (ko) * 2013-09-26 2018-07-04 파이브3 제노믹스, 엘엘씨 바이러스-연관 종양을 위한 시스템, 방법, 및 조성물

Also Published As

Publication number Publication date
JP2024531765A (ja) 2024-08-29
CA3231639A1 (en) 2023-03-23
EP4401720A4 (en) 2025-07-30
CN118159262A (zh) 2024-06-07
MX2024003333A (es) 2024-05-20
US20250127791A1 (en) 2025-04-24
WO2023043883A1 (en) 2023-03-23
US12611411B2 (en) 2026-04-28
AU2022345084A1 (en) 2024-03-28
EP4401720A1 (en) 2024-07-24
KR20240060625A (ko) 2024-05-08

Similar Documents

Publication Publication Date Title
IL280707A (en) Diagnostic and therapeutic methods for the treatment of breast cancer
ZA202206743B (en) Therapy for the treatment of cancer
DK4225297T3 (da) Kombinationsbehandling til behandling af cancer
DK3768830T5 (da) Cancerterapi
IL270697A (en) Therapeutic apoptotic cells for cancer therapy
IL307964A (en) Combined treatment for cancer
IT201900016760A1 (it) Dispositivo per il trattamento radioterapico di malati oncologici
IL281439A (en) Combined treatment for blood cancer
EP4190173C0 (en) METABOLIC THERAPY FOR CANCER
EP4440623A4 (en) Polytherapy for the treatment of cancer
EP4205812C0 (en) FULLY SPHERICAL RADIOTHERAPY SYSTEM
IL285155A (en) Metal chelator combination therapy for the treatment of cancer
HUE053648T2 (hu) Gyógyászati kombinációk rák kezelésére
IL289787A (en) Antibody combinations for treatment of cancer in specific patients
EP4041064A4 (en) A medical therapeutic device
EP4122465A4 (en) THERAPEUTIC AGENT AGAINST BREAST CANCER
EP4225129A4 (en) OCT GUIDED THERAPY
EP4401721A4 (en) CANCER TREATMENT
EP4025203A4 (en) CANCER TREATMENT
IL312249A (en) Combination therapy for treating lung cancer
EP4291301C0 (en) NON-INVASIVE CANCER TREATMENT
EP4405465A4 (en) TREATMENT METHODS
EP4200012A4 (en) Interstitial photodynamic therapy
EP4188431A4 (en) Combination therapy for cancer
EP4166147A4 (en) Sensitiser for cancer treatment